Clinical trial · Interventional
Phase I Chinese PK
An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor
NCT00503711CI-TRIAL-00023727completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid, Malignant Tumors | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vandetanib | Drug | Vandetanib | ALIAS |
| Vandetanib 300 mg | Drug | Vandetanib | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 100 mg Vandetanib eod
- description
- 100 mg Vandetanib every other day dosing
- interventionNames
- Drug: Vandetanib
- type
- EXPERIMENTAL
- label
- 100 mg Vandetanib od
- description
- 100 mg Vandetanib once daily dosing
- interventionNames
- Drug: Vandetanib
- type
- EXPERIMENTAL
- label
- 300 mg Vandetanib od
- description
- 300 mg Vandetanib once daily dosing
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histological and/or cytological confirmation of a malignant solid tumor * refractory to standard therapies or for which no appropriate therapies exist * WHO performance status 0-2 Exclusion Criteria: * patients with brain tumors or symptomatic cerebral metastases * systemic anticancer therapy within the last 4 weeks
References
Publications (1)
- BACKGROUNDZhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, Martin PD, Jiang Y, Liao H, Guan Z. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011 Mar;33(3):315-27. doi: 10.1016/j.clinthera.2011.04.005. PMID 21600385